Kancera

5,15 SEK −1,9 %

Ole ensimmäinen seuraaja

Kancera is a pharmaceutical company. The company develops pharmaceuticals that counteract injuries in acute and chronic inflammation. The products are developed primarily to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe virus infections. Kancera is planning two Phase II clinical trials, in covid-19 and in cardiac patients. Kancera conducts research and development within Karolinska Institutet Science Park in Stockholm.

Lue lisää

Liikevaihto

EBIT %

P/E -luku

Osinkotuotto %

Tavoitehinta

Suositus

Päivitetty

First North Stockholm

KAN

Päivän matalin / päivän korkein hinta

5,06 / 5,25 SEK

Markkina-arvo

419,75 milj. SEK

Vaihto

737,3 t. SEK

Vaihtomäärä, kappaletta

144 t.

Viimeisimmät videot

Kancera, Capital Markets Day, 2023

09.03.2023

Kancera, Financial hearing, 2022

08.03.2022

Dignitana, Financial hearing, 2021

24.03.2021

Pörssikalenteri

Osavuosikatsaus

17.11.2023

Vuosikatsaus

23.02.2024

Suurimmat omistajat
Lähde: Millistream Market Data AB

Omistaja	Osuus	Ääniä
Avanza Pension	9,9 %	9,9 %
Nordnet Pensionsförsäkring	2,2 %	2,2 %

Inderes Premium

Premium ei aktivoitu

Tämä sisältö on vain Inderes Premium -käyttäjille.

Kirjaudu sisään Lue lisää

Näytä Kaikki sisältötyypit

Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease

Lehdistötiedote24.07.2023

Kancera

Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology

Lehdistötiedote22.12.2022

Kancera

Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

Lehdistötiedote27.10.2022

Kancera

Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies

Lehdistötiedote27.10.2022

Kancera

Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

Pörssitiedote20.10.2022

Kancera

Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients

Lehdistötiedote27.09.2022

Kancera

Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer

Lehdistötiedote22.09.2022

Kancera

Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

Lehdistötiedote23.08.2022

Kancera

Kancera

Viimeisimmät videot

Pörssikalenteri

Suurimmat omistajat
Lähde: Millistream Market Data AB

Inderes Premium

Carlsquare: Carlsquare Equity Research: Nordic Life Science sector update

Kancera appoints new Chief Medical Officer

Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851

Kancera provides operational update in connection with release of financial interim report for second quarter

Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease

Kancera reports dosing of first patient in the KANDOVA study

Kancera appoints Peter Selin as new Chief Executive Officer

Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

Kancera reports start of patient screening for the KANDOVA-study

Kancera has submitted application to conduct First-In-Human study of KAND145

Kancera, Capital Markets Day, 2023

Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851

Carlsquare: Nordic Life science sector update

Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology

Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies

Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients

Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer

Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

Kancera

Viimeisimmät videot

Pörssikalenteri

Suurimmat omistajatLähde: Millistream Market Data AB

Inderes Premium

Carlsquare: Carlsquare Equity Research: Nordic Life Science sector update

Kancera appoints new Chief Medical Officer

Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851

Kancera provides operational update in connection with release of financial interim report for second quarter

Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease

Kancera reports dosing of first patient in the KANDOVA study

Kancera appoints Peter Selin as new Chief Executive Officer

Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

Kancera reports start of patient screening for the KANDOVA-study

Kancera has submitted application to conduct First-In-Human study of KAND145

Kancera, Capital Markets Day, 2023

Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851

Carlsquare: Nordic Life science sector update

Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology

Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies

Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients

Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer

Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

Suurimmat omistajat
Lähde: Millistream Market Data AB